மேற்கு ஜெர்மன் படிப்பு குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மேற்கு ஜெர்மன் படிப்பு குழு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மேற்கு ஜெர்மன் படிப்பு குழு Today - Breaking & Trending Today

CANKADO's Digital Health Solution Assists a New Clinical Trial, ADAPTlate


This oncologic clinical trial evaluates the efficacy and safety of the CDK 4/6 Inhibitor Abemaciclib in combination with endocrine therapy in high-risk early breast cancer patients
Cologne, Germany, 07.01.2021 – CANKADO, the leading digital health application developers in Germany, assists the recently started clinical trial, ADAPTlate, organized by West German Study Group (WSG) to collect the Patient Reported Outcomes (PROs) by the CANKADO ePRO tool. The clinical trial already enrolled the first patients who are using the CANKADO e-Health system as part of the study to monitor their Quality of Life (QoL). The trial aims to gain further knowledge on the efficacy and safety of the Abemaciclib treatment in combination with endocrine therapy versus standard endocrine therapy in HR+/HER2- early breast cancer patients with high risk for disease recurrence. ....

West German , German Study Group , European Union , Head Global Business Development , Service Gmb , Clinical Research Organisations Cros , Study Group Gmb , West German Study Group , Patient Reported Outcomes , West Study Group Gmbh , Mobile Medical , Clinical Research Organisations , மேற்கு ஜெர்மன் , ஜெர்மன் படிப்பு குழு , ஐரோப்பிய தொழிற்சங்கம் , தலை உலகளாவிய வணிக வளர்ச்சி , சேவை க்ம்ப் , மருத்துவ ஆராய்ச்சி ஆர்கநைஸேஶந்ஸ் கிராஸ் , படிப்பு குழு க்ம்ப் , மேற்கு ஜெர்மன் படிப்பு குழு , மேற்கு படிப்பு குழு கஂப் , கைபேசி மருத்துவ , மருத்துவ ஆராய்ச்சி ஆர்கநைஸேஶந்ஸ் ,

Can Genomic Tests Flag Node-Positive Breast Cancer Pts Who Can Skip Chemo?


Following is a transcript of their remarks:
Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year s San Antonio Breast Cancer meeting. I m Hope Rugo, professor of medicine at the University of California San Francisco s Comprehensive Cancer Center, and I m joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco s Comprehensive Cancer Center. Thanks for joining me today.
Now, we re going to talk about a really interesting set of presentations at San Antonio that I think really do have direct implications for clinical practice on Monday and this is the use of genomic tests and in some of the studies, Ki67 in order to try and inform us about how to treat our patients who have higher risk node-positive disease. ....

San Antonio , United States , West German , Kevin Kalinsky , Jo Chien , Jennifer Litton , Cynthia Ma , Greg Laub , Jenniferk Litton , A Jo Chien , German Study Group , Md Anderson Cancer Center , Medpage Today , San Antonio Breast Cancer , Positive Breast , Emerging Novel Therapies Presented , Hope Rugo , California San Francisco , Comprehensive Cancer Center , Cancer Center , Comprehensive Cancer , West German Study Group , Production Manager , சான் அன்டோனியோ , ஒன்றுபட்டது மாநிலங்களில் , மேற்கு ஜெர்மன் ,